Clinical Features of Alzheimer Disease With and Without Lewy Bodies
Chung EJ, Babulal GM, Monsell SE, Cairns NJ, Roe CM, Morris JC.. JAMA neurology, 2015-07-01
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Results The mean (SD) age at death was statistically significantly younger for participants who had AD with Lewy bodies (77.9 [9.5] years) than for participants who had AD without Lewy bodies (80.2 [11.1] years) (P = .01). After adjusting for age, sex, education, frequency of plaques (neuritic and diffuse), and tangle stage, we found that participants who had AD with Lewy bodies had a statistically significantly higher mean (SD) Neuropsychiatric Inventory Questionnaire score (6.59 [1.44] [95% CI, 3.75-9.42] vs 5.49 [1.39] [95% CI, 2.76-8.23]; P = .04) and a statistically significantly higher mean (SD) Unified Parkinson Disease Rating Scale motor score (0.81 [0.18] [95% CI, 0.45-1.17] vs 0.54 [0.18] [95% CI, 0.19-0.88]; P Conclusions and relevance Participants with both AD and Lewy body pathology have a clinical phenotype that may be distinguished from AD alone.
What this study adds
Evidence grade: Moderate
This is a follow-up (cohort) study. In this cohort study, people who had Alzheimer's disease with Lewy bodies had a younger age at death and higher scores for neuropsychiatric symptoms and parkinsonian motor signs than those with Alzheimer's disease alone. This describes a clinical difference between the two groups and does not offer a way to treat or prevent either condition.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Chung, E. J., Babulal, G. M., Monsell, S. E., Cairns, N. J., Roe, C. M., & Morris, J. C. (2015). Clinical Features of Alzheimer Disease With and Without Lewy Bodies. JAMA neurology. https://doi.org/10.1001/jamaneurol.2015.0606
Vancouver
Chung EJ, Babulal GM, Monsell SE, Cairns NJ, Roe CM, Morris JC. Clinical Features of Alzheimer Disease With and Without Lewy Bodies. JAMA neurology. 2015. doi:10.1001/jamaneurol.2015.0606. PMID: 25985321.
BibTeX
@article{chung2015-25985321,
author = {Chung, E. J. and Babulal, G. M. and Monsell, S. E. and Cairns, N. J. and Roe, C. M. and Morris, J. C.},
title = {{Clinical Features of Alzheimer Disease With and Without Lewy Bodies}},
journal = {JAMA neurology},
year = {2015},
doi = {10.1001/jamaneurol.2015.0606},
pmid = {25985321},
url = {https://doi.org/10.1001/jamaneurol.2015.0606}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Results The mean (SD) age at death was statistically significantly younger for participants who had AD with Lewy bodies (77.9 [9.5] years) than for participants who had AD without Lewy bodies (80.2 [11.1] years) (P = .01).
- After adjusting for age, sex, education, frequency of plaques (neuritic and diffuse), and tangle stage, we found that participants who had AD with Lewy bodies had a statistically significantly higher mean (SD) Neuropsychiatric Inventory Questionnaire score (6.59 [1.44] [95% CI, 3.75-9.42] vs 5.49 [1.39] [95% CI, 2.76-8.23]; P = .04) and a statistically significantly higher mean (SD) Unified Parkinson Disease Rating Scale motor score (0.81 [0.18] [95% CI, 0.45-1.17] vs 0.54 [0.18] [95% CI, 0.19-0.88]; P < .001) than did participants who had AD without Lewy bodies.
Why it matters
In this cohort study, people who had Alzheimer's disease with Lewy bodies had a younger age at death and higher scores for neuropsychiatric symptoms and parkinsonian motor signs than those with Alzheimer's disease alone. This describes a clinical difference between the two groups and does not offer a way to treat or prevent either condition.
New to this subject? Start with our plain-English guide: Genetics →
Study details
- Study designcohort study
- Evidence strengthModerate
How this study scored 59/100
Published in a leading specialty journal, and it is a cohort study following people over time. Scored zero for sample size, effect reported, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (JAMA neurology) |
| Journal's citation record | 2 / 4 | JAMA Neurology: journal h-index 235 (OpenAlex, 2026-10-29) |
| Study design | 7 / 12 | A cohort study following people over time |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2015 — within 20 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 5 / 7 | Cited 127 times (OpenAlex, 2026-10-10) |
| Citations per year | 3 / 5 | 9.8 citations a year over 13 year(s) since 2015 |
| Impact for its field and year | 3 / 6 | Cited 6.8× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 2 / 6 | Cited by 9 other studies in this library |
| Still being cited | 3 / 4 | Cited 51 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 4 / 4 | Last-listed author John C. Morris: h-index 209 (OpenAlex, whole career) |
| Institution's track record | 3 / 3 | University of Washington: institution h-index 3,540 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 4 institution(s) in 2 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 25985321) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 59 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1001/jamaneurol.2015.0606
- PubMed: 25985321
- Original source →
- Free full text: PubMed Central →
Full text: free to read — PubMed Central lists this copy as free to read: the link above (checked 10 Oct 2026).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 24.
Later studies that cite this one
9 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.
Related studies in Genetics from nearby years
Also in Genetics
198 studies in the library are filed under Genetics with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Genetics hub.